Viewing Study NCT06590558


Ignite Creation Date: 2025-12-25 @ 12:16 AM
Ignite Modification Date: 2026-01-04 @ 3:39 PM
Study NCT ID: NCT06590558
Status: WITHDRAWN
Last Update Posted: 2025-07-03
First Post: 2024-09-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Sponsor: National Cancer Institute (NCI)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module